Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Herman

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.
Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Blood|January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cellsSivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Leukemia & Lymphoma|March 11, 2017
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemiaFie J Vojdeman, Sarah E M Herman, Nikolai Kirkby, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Leukemia|January 12, 2017
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodThomas M Herndon, Shih-Shih Chen, Nakhle S Saba, et al.
Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Blood|January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cellsSivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Leukemia & Lymphoma|March 11, 2017
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemiaFie J Vojdeman, Sarah E M Herman, Nikolai Kirkby, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Pageof 10